Madrigal Pharmaceuticals, Inc.
MDGL
Rankning i aktier
#1952
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Aktiekurs
$458.30
Senast synkroniserad: 2026-10-21
Marknadsvärde
$10.59B
Förändring (1 dag)
-1.98%
Förändring (1 år)
10.18%
Land
US
Handel Madrigal Pharmaceuticals, Inc. (MDGL)
Kategori
Healthcare
Aktiekurshistorik för Madrigal Pharmaceuticals, Inc. (MDGL)
Högsta slutkurs: $472.49 den 2026-10-01
Lägsta slutkurs: $322.31 den 2007-02-01
Lägsta slutkurs: $322.31 den 2007-02-01
Aktiekurshistorik för Madrigal Pharmaceuticals, Inc. från 2007 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | -11.50% |
| 2025 | 85.56% |
| 2024 | 36.19% |
| 2023 | 46.99% |
| 2022 | 95.20% |
| 2021 | -32.68% |
| 2020 | 16.63% |
| 2019 | -6.63% |
| 2018 | 32.71% |
| 2017 | 414.16% |
| 2016 | 26.67% |
| 2015 | -87.18% |
| 2014 | -42.14% |
| 2013 | -44.12% |
| 2012 | 87.26% |
| 2011 | -19.61% |
| 2010 | 10.34% |
| 2009 | 1.71% |
| 2008 | -25.83% |
| 2007 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.97 | 7.73% |
CH
|
